Tuning the Immune System to Fight Cancer

Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence

 

Tuning the Immune System to Fight Cancer

Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence

 

Our approach

NeoVAC

Immunetune is developing best-in-class personalized DNA vaccines harboring more than 20 neoantigens to elicit powerful tumor-specific immune responses.

read more

Proprietary Technology

NeoVAC, our main product in development, which is aimed to enter the clinic in 2020, is developed utilizing our proprietary PersoVax™, AmpliVax™, Pyrovant™ and CADVax™ technologies.

read more

Unique Differentiators

DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide/RNA vaccines, or cell-based immunotherapies.

read more

Company Highlights

Extensive pre-clinical package available showing proof of concept.

Proprietary, optimized vaccine design devoid of any bacterial sequences and incorporating multiple antigens.

DNA vaccination synergizes with checkpoint inhibition and provides long-term tumor protection.

Patent applications filed on cell-free and scalable production platform for DNA vaccines and novel genetic adjuvants.

Currently preparing for clinical studies and seeking partners and/or funding for next steps and company upscaling.

About Us

Company Background

Immunetune, based in Leiden, the Netherlands, is a dedicated and fast-moving biotech company committed to develop personalized, tumor-specific vaccines to fight cancer and prevent its recurrence.

read more

Our Team

Highly motivated team combining corporate and scientific expertise. Immunetune scientists have vast expertise in immunology, molecular biology, and a long-standing collaboration with Leiden University Medical Center.

read more

News

Biotech Wednesday: Joining forces to outsmart cancer

Biotech Wednesday: Joining forces to outsmart cancer

Immunetune will be attending Biotech Wednesday on November 20 in Utrecht, the Netherlands. Reach out to us through the networking app or contact us directly in case you'd like to learn more about Immunetune's approach to fight cancer. More information on this meeting...

read more
Bio-Europe, Nov 11-13 in Hamburg

Bio-Europe, Nov 11-13 in Hamburg

Gerben C.M. Zondag, CEO of Immunetune, will attend the BIO-Europe meeting in Hamburg, November 11-13, 2019.   Feel free to request a meeting if you'd like to hear more about possible partnering of investment opportunities.

read more

Contact us

I hereby confirm that I have fully read and accept Immunetune's privacy statement.

Click here to read our privacy statement.